Prevalence of Different Haptoglobin Phenotypes in Patients With COPD- Frequent Exacerbators Versus Non Exacerbators
NCT01745419 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 105
Last updated 2016-07-28
Summary
Chronic obstructive pulmonary disease (COPD) is a common disease in smokers. COPD has a slowly deteriorating course, punctuated by exacerbations- acute events characterized by increasing shortness of breath and putrid sputum. Exacerbations of COPD may be precipitated by several factors, most commonly infections.
Exacerbation frequency generally increases with declining lung function. However, some patients with COPD consistently experience a higher rate of exacerbations than others despite similar severity of COPD. This has led researchers to postulate the existence of a distinct subgroup of "frequent exacerbators" . Recent work has also brought attention to a subset of patients who experience remarkably few exacerbations despite significantly impaired lung function. Careful characterization of both of these extreme subgroups of COPD may offer additional insights into why certain patients are prone to frequent exacerbations while others remain relatively protected.
Haptoglobin (Hp) is a protein produced predominately by the liver . In humans two types of genes for Hp exist (1 and 2) with possible combinations of these two genes- 1-1, 1-2, or 2-2. The Hp 2 gene is believed to have arisen from the Hp 1 gene in human evolution. Subsequently the prevalence of the Hp 2 allele has spread throughout the world, probably as a result of its ability to provide a selective advantage against infectious disease. The Hp 1-2 combination is a very common one. In most western countries, the prevalence of the Hp genotypes is 16% Hp 1-1, 36% Hp 2-2 and 48% Hp 2-1.
The Hp gene form has been shown to be associated with disease. Specifically, Hp phenotypes have been found to affect propensity to atherosclerosis in Diabetic individuals. There have been several studies suggesting that the Hp 2-2 phenotype is associated with a protection against infectious complications.
In view of the importance of respiratory infections on COPD exacerbations, and of the gained knowledge of Haptoglobin subtypes on propensity to infection, we propose to investigate whether Haptoglobin subtypes are in correlation with the "frequent exacerbator" phenotype of COPD. We postulate that, since people with Hp 1-1 are more prone to infection, the frequency of the Hp 1-1 phenotype will be higher in "frequent exacerbators" of COPD than in "non- exacerbators".
To test our hypothesis we propose to determine Hp phenotype in two groups of COPD patients: one with frequent exacerbations and one with no exacerbations, and compare the relative frequency of the 1-1 phenotype in the two groups.
Conditions
- Pulmonary Disease, Chronic Obstructive
Sponsors & Collaborators
-
Technion, Israel Institute of Technology
collaborator OTHER -
Carmel Medical Center
lead OTHER
Principal Investigators
-
Michal Shteinberg, MD, PhD · Pulmonology Institute, Carmel Medical Center
Eligibility
- Min Age
- 40 Years
- Max Age
- 90 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2013-01-31
- Primary Completion
- 2015-01-31
- Completion
- 2016-06-30
Countries
- Israel
Study Locations
More Related Trials
-
Validation of Chronic Obstructive Pulmonary Disease (COPD) Algorithm
NCT07223749 ·Status: RECRUITING
-
Domiciliary Monitoring to Predict Exacerbations of COPD
NCT03003702 ·Status: COMPLETED ·Phase: NA
-
The Mixed Phenotype of Asthma and COPD: the Overlap Syndrome
NCT03817333 ·Status: COMPLETED
-
Cough Frequency in Chronic Obstructive Pulmonary Disease
NCT01405222 ·Status: COMPLETED
-
Predicting Risk Factors for Exacerbation of Chronic Obstructive Pulmonary Disease
NCT03450603 ·Status: RECRUITING
-
Bronchial Infection in Patients With COPD and Frequent Exacerbations.
NCT03259022 ·Status: UNKNOWN
-
Young Smokers Have Impaired Airway Defense
NCT01877291 ·Status: COMPLETED
-
COPD Metabolome, Smoking Oxidants and Aberrant Ciliated Cell Function
NCT01974154 ·Status: TERMINATED
-
Factors That Affect the Development of COPD Symptoms
NCT00740337 ·Status: COMPLETED
-
Identifying Patients With the COPD-Asthma Overlap Phenotype: Therapeutic Implications
NCT02985814 ·Status: COMPLETED
-
Exacerbations and Health Related Quality of Life in Chronic Obstructive Pulmonary Disease
NCT00884975 ·Status: UNKNOWN
-
Exploring Clinical Predictors of COPD Exacerbation in a Community Cohort
NCT05762861 ·Status: UNKNOWN ·Phase: NA
-
Preventing Repeat Hospitalisations in Patients With Chronic Obstructive Pulmonary Disease (COPD)
NCT02644772 ·Status: COMPLETED
-
Phenotypes of COPD
NCT03432026 ·Status: UNKNOWN
-
Phenotypic Measurements and Their Relation to Disease Exacerbation in COPD Patients
NCT03300739 ·Status: COMPLETED
-
Evaluation of Immunological, Microbiological and Metabolomic Profiles in COPD
NCT06826560 ·Status: COMPLETED
-
Pulmonary Function Changes in 10 Pack Year Smokers With Chronic Bronchitis
NCT00454675 ·Status: COMPLETED
-
Chronic Obstructive Pulmonary Disease and Pulmonary Hypertension: Prevalence and Quality of Life
NCT01423071 ·Status: COMPLETED
-
Dyspnea in Patients With Pulmonary Fibrosis
NCT00611182 ·Status: COMPLETED
-
Biological Markers for Professional COPD
NCT03240198 ·Status: UNKNOWN
-
Prevalence of Bronchiectasis in COPD Patients
NCT04101448 ·Status: UNKNOWN
-
Lung Macrophage Populations and Functions in Chronic Obstructive Pulmonary Disease (COPD)-Susceptible Smokers
NCT04722835 ·Status: UNKNOWN
-
COPD and Cardiovascular Risk in the Population
NCT00787748 ·Status: COMPLETED
-
Cardiovascular Risk and Chronic Obstructive Pulmonary Disease
NCT03014609 ·Status: RECRUITING
-
Pulmonary Disease in Patients Referred for Coronary CT
NCT01734629 ·Status: COMPLETED